86
5
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T40264 | CDK7-IN-7 | CDK7-IN-7 | |
CDK7-IN-7, a highly potent and selective inhibitor of CDK7 kinase, exhibits remarkable activity with an IC50 of less than 50 nM. | |||
T39943 | CDK7-IN-6 | CDK7-IN-6 | |
CDK7-IN-6 is a highly effective and specific inhibitor (IC50 ≤100 nM) of cyclin-dependent kinase 7 (CDK7). It showcases remarkable selectivity, with more than a 200-fold preference for CDK7 over CDK1, CDK2, and CDK5. Thi... | |||
T39372 | CDK7-IN-1 | CDK7-IN-1 | |
CDK7-IN-1 is an analog derived from YKL-5-124 and functions as an inhibitor of cyclin-dependent kinase 7 (cdk7). It exhibits strong inhibitory activity, with an IC50 value of less than 100 nM (WO 2016105528 A2, Compound ... | |||
T39247 | CDK7-IN-5 | CDK7-IN-5 | |
CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104). | |||
T40353 | CDK7/9-IN-1 | CDK7/9-IN-1 | |
CDK7/9-IN-1 is a specific inhibitor of cyclin-dependent kinases 7/9 (CDK7/9). It specifically targets CDK7, while also displaying inhibitory activity against CDK9. CDK7/9-IN-1 demonstrates excellent inhibitory potency ag... | |||
T36038 | SY-5609 | CDK7-IN-3 | CDK |
SY-5609 is a selective and noncovalent inhibitor of CDK7(KD = 0.065 nM) with antitumor activity and inhibits apoptosis. | |||
T7296 | THZ2 | CDK7-IN-1 | CDK |
THZ2 (CDK7-IN-1), an analog of THZ1, is a potent and selective CDK7 inhibitor(IC50:13.9 nM),with the potential to treat Triple-negative breast cancer (TNBC). | |||
T39864 | CDK7-IN-2 hydrochloride hydrate | CDK7-IN-2 hydrochloride hydrate | |
CDK7-IN-2 hydrochloride hydrate (Example 6) is a highly effective and specific inhibitor of the CDK7 enzyme. This compound exhibits significant anti-cancer properties. | |||
T3664 | THZ1 | CDK7 inhibitor,THZ1 2HCl | CDK |
THZ1 (CDK7 inhibitor) is a novel selective and potent covalent CDK7 inhibitor. | |||
T36743 | CDK7/9 tide | ||
CDK7/9 tide is peptide substrate for CDK7 or CDK9[1]. [1]. Robert T, et, al. Development of a CDK10/CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors. Front Chem. 2020 Feb 27; 8:1... | |||
T79169 | CDK7-IN-22 | CDK | |
CDK7-IN-22 (compound 101) is a selective CDK7 inhibitor that exhibits antitumor activity, demonstrating specificity for CDK7 [1]. | |||
T75121 | CDK7-IN-21 | ||
CDK7-IN-21 (compound A22) is a potent CDK7 inhibitor [1] . | |||
T63410 | CDK7-IN-17 | ||
CDK7-IN-17 is a pyrimidine-derived compound and a potent inhibitor of CDK7. CDK7-IN-17 has shown research potential for a variety of cancers, particularly those with dysregulated transcription. | |||
T63108 | CDK7-IN-14 | ||
CDK7-IN-14 is a pyrimidine-derived compound that is a potent inhibitor of CDK7. CDK7-IN-14 has the potential to be investigated in a variety of cancers, particularly those with transcriptional dysregulation. | |||
T63381 | CDK7-IN-8 | ||
CDK7-IN-8 is a potent inhibitor of CDK7 (IC50: 54.29 nM) and exhibits inhibitory activity against several cancer cells and in vivo tumor models. | |||
T63301 | CDK7-IN-18 | ||
CDK7-IN-18 is a pyrimidine-derived compound that is a potent inhibitor of CDK7. CDK7-IN-18 exhibits potential for research in a variety of cancers, particularly those with dysregulated transcription. | |||
T79881 | CDK7-IN-25 | CDK | |
CDK7-IN-25 (CY-16-1) is a potent CDK7 inhibitor with an IC50 value of less than 1nM, utilized in cancer research [1]. | |||
T62791 | CDK7-IN-16 | ||
CDK7-IN-16 (Compound 9) is a potent inhibitor of CDK 7 (IC50: 1-10 nM). CDK7-IN-16 can be used in research against cancer, particularly cancers with transcriptional abnormalities. | |||
T63724 | CDK7-IN-10 | ||
CDK7-IN-10 is a CDK7 inhibitor (IC50<100 nM). CDK7-IN-10 inhibits kinase activity and has the potential to inhibit cell growth and induce apoptosis. | |||
T61922 | CDK7-IN-12 | ||
CDK7-IN-12 is an effective CDK7 inhibitor and plays a key role in regulating transcription and cell cycle. CDK7-IN-12 can effectively inhibit the proliferation of malignant tumors in vitro and in vivo. CDK7-IN-12 has res... | |||
T63217 | CDK7-IN-15 | ||
CDK7-IN-15 is a pyrimidine-derived compound and a potent inhibitor of CDK7. CDK7-IN-15 has the potential to be investigated in a variety of cancers, particularly those with dysregulated transcription. | |||
T62759 | CDK7-IN-13 | ||
CDK7-IN-13 is a pyrimidine-derived compound that is a potent inhibitor of CDK7. CDK7-IN-13 has the potential to be investigated in a variety of cancers (particularly those with dysregulated transcription). | |||
T63368 | CDK7-IN-2 | ||
CDK7-IN-2 is a potent inhibitor of CDK7. CDK7 is involved in transcription initiation using phosphorylation of the Rbpl subunit of RNA polymerase II (RNAPII), which is associated with temporal control of cell cycle and t... | |||
T73163 | CDK7-IN-20 | ||
CDK7-IN-20 is a potent, selective, and irreversible inhibitor of Cyclin-Dependent Kinase 7 (CDK7) with an IC50 value of 4 nM, exhibiting over 206-fold selectivity against related kinases CDK1, CDK2, CDK3, CDK5, CDK6, CDK... | |||
T82227 | HDAC1/CDK7-IN-1 | HDAC | |
HDAC1/CDK7-IN-1 (compound 8e) serves as a dual inhibitor targeting both CDK7 and HDAC1, with IC50 values of 893 nM and 248 nM , respectively. This compound effectively suppresses the proliferation of various cancer cell... | |||
T62926 | CDK7/12-IN-1 | ||
CDK7/12-IN-1 is a selective inhibitor of CDK7/12, acting on CDK7 (IC50: 3 nM) and CDK 12 (IC50: 277 nM). Inhibition of CDK7 and CDK12 is an effective inhibitor of tumour growth. | |||
T22461 | YKL-5-124 | CDK | |
YKL-5-124, a potent, selective and covalent CDK7 inhibitor with an IC50 of 9.7 nM, 1300 nM and 3020 nM for CDK7/Mat1/CycH, CDK2 and CDK9 respectively, displays biochemical and cellular selectivity for CDK7 over CDK12/13... | |||
T13044 | Mevociclib | SY-1365 | CDK |
Mevociclib (SY-1365) is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors. | |||
T10898 | Samuraciclib hydrochloride | ICEC0942 hydrochloride,CT7001 hydrochloride | Apoptosis , CDK |
Samuraciclib hydrochloride (ICEC0942 hydrochloride) is a potent, selective, ATP competitive and oral active CDK7 inhibitor with IC50 of 41 nM. The selectivity of Samuraciclib hydrochloride is 45-, 15-, 230- and 30-fold h... | |||
T4051 | LDC4297 | LDC044297 | CDK , HSV |
LDC4297 (LDC044297) is a potent and selective CDK7 inhibitor. | |||
T4417 | LDC-4297 HCl (1453834-21-3(free base)) | CDK | |
LDC4297 is a potent and selective CDK7 inhibitor with an IC50 of 0.13 nM. | |||
T6162 | BS-181 hydrochloride | BS-181 HCl | CDK |
BS-181 hydrochloride (BS-181 HCl) is a highly selective CDK7 inhibitor with IC50 of 21 nM. It is more than 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9. | |||
T35332 | THZ1 2HCl | THZ1 2HCl,THZ1 Dihydrochloride | CDK |
THZ1 2HCl (THZ1 Dihydrochloride) is a selective, covalent, and allosteric inhibitor of CDK7 with an IC50 of 3.2 nM. THZ1 2HCl has antiproliferative effects on a variety of cancer cell lines. | |||
TQ0060 | LY2857785 | Apoptosis , CDK | |
LY2857785 is a type I competitive and reversible ATP kinase inhibitor against CDK7/CDK8/CDK9 (IC50s: 246 nM/16 nM/11 nM). | |||
T6049 | SNS-032 | SNS032,BMS-387032 | Apoptosis , GSK-3 , CDK |
SNS-032 (BMS-387032) is a selective inhibitor of CDK2 (IC50: 48 nM ) and is 10- and 20-fold selective over CDK1/CDK4. It is also sensitive to CDK7/9 (IC50: 62 nM/4 nM), and no effect on CDK6. | |||
T22440 | TP-353 | EOS-61973 | CDK |
TP-353 (EOS-61973) is a CDK7 inhibitor. | |||
T2095 | Seliciclib | Roscovitine,R-roscovitine,CYC202 | CDK |
Seliciclib (Roscovitine) is a potent inhibitor of Cdk2/cyclin E (IC50: 0.1 μM). It also inhibits Cdk7/cyclin H, Cdk5/p35, and Cdc2/cyclin B (IC50s: 0.49/0.16/0.65 μM). | |||
T9078 | LY3405105 | 1-Piperidinecarboxylic acid, 4-[[5-methyl-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 1-[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]-3-pyrrolidinyl ester | CDK |
LY3405105 (1-Piperidinecarboxylic acid, 4-[[5-methyl-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 1-[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]-3-pyrrolidinyl ester) is a novel CDK7 inhibitors. | |||
T39752 | CDK12-IN-2 | CDK12 inhibitor 2,CDK12-IN-2 | CDK |
CDK12-IN-2 (CDK12 inhibitor 2) is an effective and selective inhibitor of CDK12 with an IC50 of 52 nM, >100 μM, >10 μM and 16 μM for CDK12, CDK2, CDK7, and CDK9. CDK12-IN-2 can be used in studies about the function of CD... | |||
T6837 | Flavopiridol | L868275,Alvocidib,NSC 649890 HCl,HMR-1275 | Apoptosis , HIV Protease , CDK , Autophagy |
Flavopiridol (Alvocidib) (Alvocidib) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1, 2, 4, 6 versus CDK7. Flavopiridol is initially foun... | |||
T6205 | AT7519 | Apoptosis , GSK-3 , CDK | |
AT7519 is a CDK1/2/4/6/9 inhibitor (IC50: 10-210 nM). It is less effective to CDK3 and little active to CDK7. | |||
T6312 | R547 | Ro 4584820 | Apoptosis , GSK-3 , PKA , CDK |
R547 (Ro 4584820) is a potent ATP-competitive inhibitor of CDK1/2/4 with Ki of 2 nM/3 nM/1 nM. It is less potent to CDK7 and GSK3α/β, while inactive to other kinases. Phase 1. | |||
T2378 | RGB-286638 free base | GSK-3 , MEK , JAK , CDK | |
RGB-286638 free base is a novel CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3/p35-CDK5 respectively; less potent against cyclin H-CDK7 a... | |||
T14943 | CGP60474 | VEGFR , CDK , PKC | |
CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC. CGP60474 is also a highly potent anti-endotoxemic agent and inhibits cyclin-dependent kinase (CDK) potently. | |||
T13153 | THZ1-R | CDK | |
THZ1-R displays diminished activity for CDK7 inhibition(Kd:142 nM). | |||
T1947 | BS-181 | BS 181 | Apoptosis , CDK |
BS-181 is a highly selective CDK7 inhibitor (IC50: 21 nM); >40-fold selective for CDK7 than CDK1/2/4/5/6/9. | |||
T13367 | YKL-5-124 TFA (1957203-01-8 free base) | YKL-5-124 TFA | Others |
YKL-5-124 TFA is a potent, selective, irreversible and covalent inhibitor of CDK7 (IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively). | |||
T39456 | IV-361 | ||
IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1). | |||
T24643 | YKL-1-116 | YKL 1 116,YKL1116 | |
YKL-1-116 is an effective, selective, and covalent CDK7 inhibitor. | |||
T14915 | CDK12-IN-E9 | CDK | |
CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and non-covalent CDK9 inhibitor while avoiding ABC transporter-mediated efflux. It has a weak binding ability to CDK7/CyclinH complex (IC50> 1 μM). |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPH-01172 | CDK7 Protein, Human, Recombinant (His) | Human | Baculovirus Insect Cells |
CDK7 Protein, Human, Recombinant (His) is expressed in Baculovirus. | |||
TMPH-01173 | CDK7 Protein, Human, Recombinant | Human | E. coli |
CDK7 Protein, Human, Recombinant is expressed in E. coli. | |||
TMPY-04449 | CDK7 & CCNH & MNAT1 Protein, Human, Recombinant (His) | Human | Baculovirus Insect Cells |
CDK7 & CCNH & MNAT1 Protein, Human, Recombinant (His) is expressed in Baculovirus insect cells with His tag. The predicted molecular weight is 118.8 kDa and the accession number is P50613&P51946&P51948. | |||
TMPH-02574 | P53 Protein, Mouse, Recombinant (His & SUMO) | Mouse | E. coli |
Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negativel... | |||
TMPH-03264 | P53 Protein, Rat, Recombinant (His) | Rat | E. coli |
Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negativel... |